Occupe actuellement des postes chez Myovant Sciences Ltd and Celgene Corp
Position | Company | Period |
---|---|---|
Independent Director | Myovant Sciences Ltd | 15 novembre 2016 - |
President, Global Inflammation & Immunology Franchise | Celgene Corp | 1 avril 2017 - |
Rechercher
Date de notification | Date de transaction | A/V Type de transaction |
Nb. d'actions Prix Valeur |
Nombre d'actions | Prix | Valeur totale | Détails | |
---|---|---|---|---|---|---|---|---|
2024-03-26 | 2024-03-22 |
Phathom Pharmaceuticals Inc
(PHAT)
|
VP Vente planifiée |
16 851
-3.9%
9,11153 513 USD |
16 851 -3.9% | 9,11 | 153 513 USD | |
2023-04-07 | 2023-04-06 |
Phathom Pharmaceuticals Inc
(PHAT)
|
A Achat |
12 919
+7.4%
7,82101 025 USD |
12 919 +7.4% | 7,82 | 101 025 USD | |
2023-03-03 | 2023-03-01 |
Phathom Pharmaceuticals Inc
(PHAT)
|
VP Vente planifiée |
1 436
-0.8%
8,5412 265 USD |
1 436 -0.8% | 8,54 | 12 265 USD | |
2023-01-20 | 2023-01-20 |
Phathom Pharmaceuticals Inc
(PHAT)
|
V Vente |
5 821
-3.2%
8,2047 729 USD |
5 821 -3.2% | 8,20 | 47 729 USD | |
2022-11-23 | 2022-11-21 |
Phathom Pharmaceuticals Inc
(PHAT)
|
V Vente |
1 526
-1.8%
9,6014 650 USD |
1 526 -1.8% | 9,60 | 14 650 USD | |
2022-05-16 | 2022-05-13 |
Phathom Pharmaceuticals Inc
(PHAT)
|
A Achat |
20 500
+46.5%
7,41151 835 USD |
20 500 +46.5% | 7,41 | 151 835 USD | |
2021-09-13 | 2021-09-09 |
Myovant Sciences Ltd
(MYOV)
|
VP Vente planifiée |
4 850
-100.0%
25,58124 063 USD |
4 850 -100.0% | 25,58 | 124 063 USD | |
2021-03-23 | 2021-03-22 |
Phathom Pharmaceuticals Inc
(PHAT)
|
V Vente |
1 140
-100.0%
44,0850 256 USD |
1 140 -100.0% | 44,08 | 50 256 USD | |
2021-03-23 | 2021-03-22 |
Phathom Pharmaceuticals Inc
(PHAT)
|
VP Vente planifiée |
10 373
-90.1%
43,24448 495 USD |
10 373 -90.1% | 43,24 | 448 495 USD | |
2019-09-19 | 2019-09-18 |
Celgene Corp
(CELG)
|
V Vente |
6 838
-76.0%
98,31672 244 USD |
6 838 -76.0% | 98,31 | 672 244 USD | |
2019-09-19 | 2019-09-18 |
Celgene Corp
(CELG)
|
V Vente |
4 500
-33.4%
98,20441 900 USD |
4 500 -33.4% | 98,20 | 441 900 USD |